Evidence map›Paper›PMID 32214855›Full record

ArticleInternational medical case reports journal2020

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib.

Pietro Di Marino, Gianluca Mannetta, Consiglia Carella, Antonino Grassadonia, Nicola Tinari, Clara Natoli, Michele De Tursi

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International medical case reports journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Pietro Di MarinoClinical Oncology Unit, S.S. Annunziata Hospital, Chieti, Italy.
Gianluca MannettaDepartment of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University, Chieti, Italy.
Consiglia CarellaDepartment of Medical, Oral and Biotechnological Sciences University "G. D'Annunzio", Chieti-Pescara, Italy.
Antonino GrassadoniaDepartment of Medical, Oral and Biotechnological Sciences University "G. D'Annunzio", Chieti-Pescara, Italy.
Nicola TinariDepartment of Medical, Oral and Biotechnological Sciences University "G. D'Annunzio", Chieti-Pescara, Italy.ORCID 0000-0001-8449-5407
Clara NatoliDepartment of Medical, Oral and Biotechnological Sciences University "G. D'Annunzio", Chieti-Pescara, Italy.
Michele De TursiDepartment of Medical, Oral and Biotechnological Sciences University "G. D'Annunzio", Chieti-Pescara, Italy.ORCID 0000-0002-1411-1946
University of Chieti-Pescara · ITOspedale SS. Annunziata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCrizotinib is the first tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase ( CASE PRESENTATION: We herein report the case of a 74-year-old woman who received crizotinib for metastatic

conclusionIt would seem that alectinib is able to reduce in size and number hepatic and renal cysts caused by the crizotinib treatment. Nevertheless, further studies are needed to clarify the role of both crizotinib in the onset of renal and hepatic cysts and alectinib in their disappearance.

Indexed as

alectinibanaplastic lymphoma kinasecrizotinibhepatic cystsnon-small-cell lung cancerrenal cysts

Identifiers

PMID32214855
PMCPMC7083626
OpenAlexW3010729591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.